Phathom Pharmaceuticals Inc
NASDAQ:PHAT

Watchlist Manager
Phathom Pharmaceuticals Inc Logo
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Watchlist
Price: 9.28 USD -4.82%
Market Cap: 553m USD
Have any thoughts about
Phathom Pharmaceuticals Inc?
Write Note

Intrinsic Value

PHAT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one PHAT stock under the Base Case scenario is 12.09 USD. Compared to the current market price of 9.28 USD, Phathom Pharmaceuticals Inc is Undervalued by 23%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PHAT Intrinsic Value
12.09 USD
Undervaluation 23%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Phathom Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PHAT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PHAT?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Phathom Pharmaceuticals Inc

Provide an overview of the primary business activities
of Phathom Pharmaceuticals Inc.

What unique competitive advantages
does Phathom Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Phathom Pharmaceuticals Inc face in the near future?

Summarize the latest earnings call
of Phathom Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Phathom Pharmaceuticals Inc.

Provide P/S
for Phathom Pharmaceuticals Inc.

Provide P/E
for Phathom Pharmaceuticals Inc.

Provide P/OCF
for Phathom Pharmaceuticals Inc.

Provide P/FCFE
for Phathom Pharmaceuticals Inc.

Provide P/B
for Phathom Pharmaceuticals Inc.

Provide EV/S
for Phathom Pharmaceuticals Inc.

Provide EV/GP
for Phathom Pharmaceuticals Inc.

Provide EV/EBITDA
for Phathom Pharmaceuticals Inc.

Provide EV/EBIT
for Phathom Pharmaceuticals Inc.

Provide EV/OCF
for Phathom Pharmaceuticals Inc.

Provide EV/FCFF
for Phathom Pharmaceuticals Inc.

Provide EV/IC
for Phathom Pharmaceuticals Inc.

Show me price targets
for Phathom Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Phathom Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Phathom Pharmaceuticals Inc?

What are the Net Income projections
for Phathom Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Phathom Pharmaceuticals Inc?

What are the EPS projections
for Phathom Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Phathom Pharmaceuticals Inc?

What are the EBIT projections
for Phathom Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Phathom Pharmaceuticals Inc?

Compare the revenue forecasts
for Phathom Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Phathom Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Phathom Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Phathom Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Phathom Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Phathom Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Phathom Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Phathom Pharmaceuticals Inc.

Provide ROE
for Phathom Pharmaceuticals Inc.

Provide ROA
for Phathom Pharmaceuticals Inc.

Provide ROIC
for Phathom Pharmaceuticals Inc.

Provide ROCE
for Phathom Pharmaceuticals Inc.

Provide Gross Margin
for Phathom Pharmaceuticals Inc.

Provide Operating Margin
for Phathom Pharmaceuticals Inc.

Provide Net Margin
for Phathom Pharmaceuticals Inc.

Provide FCF Margin
for Phathom Pharmaceuticals Inc.

Show all solvency ratios
for Phathom Pharmaceuticals Inc.

Provide D/E Ratio
for Phathom Pharmaceuticals Inc.

Provide D/A Ratio
for Phathom Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Phathom Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Phathom Pharmaceuticals Inc.

Provide Quick Ratio
for Phathom Pharmaceuticals Inc.

Provide Current Ratio
for Phathom Pharmaceuticals Inc.

Provide Cash Ratio
for Phathom Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Phathom Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Phathom Pharmaceuticals Inc?

What is the current Free Cash Flow
of Phathom Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Phathom Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Phathom Pharmaceuticals Inc

Current Assets 373.8m
Cash & Short-Term Investments 334.7m
Receivables 21.1m
Other Current Assets 18.1m
Non-Current Assets 13.2m
PP&E 2.5m
Other Non-Current Assets 10.7m
Current Liabilities 65.3m
Accounts Payable 7.1m
Accrued Liabilities 38m
Other Current Liabilities 20.2m
Non-Current Liabilities 508.9m
Long-Term Debt 498.1m
Other Non-Current Liabilities 10.8m
Efficiency

Earnings Waterfall
Phathom Pharmaceuticals Inc

Revenue
26.3m USD
Cost of Revenue
-4.3m USD
Gross Profit
21.9m USD
Operating Expenses
-309.9m USD
Operating Income
-287.9m USD
Other Expenses
-51.5m USD
Net Income
-339.4m USD

Free Cash Flow Analysis
Phathom Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

PHAT Profitability Score
Profitability Due Diligence

Phathom Pharmaceuticals Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Year Average ROIC
Exceptional Revenue Growth Forecast
Exceptional ROE
58/100
Profitability
Score

Phathom Pharmaceuticals Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

PHAT Solvency Score
Solvency Due Diligence

Phathom Pharmaceuticals Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Positive Net Debt
Long-Term Solvency
40/100
Solvency
Score

Phathom Pharmaceuticals Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PHAT Price Targets Summary
Phathom Pharmaceuticals Inc

Wall Street analysts forecast PHAT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PHAT is 23.02 USD with a low forecast of 12.12 USD and a high forecast of 29.4 USD.

Lowest
Price Target
12.12 USD
31% Upside
Average
Price Target
23.02 USD
148% Upside
Highest
Price Target
29.4 USD
217% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PHAT?

Click here to dive deeper.

Dividends

Phathom Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for PHAT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Phathom Pharmaceuticals Inc Logo
Phathom Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

547m USD

Dividend Yield

0%

Description

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 77 full-time employees. The company went IPO on 2019-10-25. The Company’s pipeline product candidate, vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has an anti-secretory effect and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Contact

NEW JERSEY
Florham Park
100 Campus Drive,, Suite 102
+18777428466.0
www.phathompharma.com

IPO

2019-10-25

Employees

77

Officers

President, CEO & Director
Ms. Terrie J. Curran
Co-Founder & Director
Mr. David A. Socks
Co-Founder & COO
Dr. Azmi Nabulsi M.D., M.P.H.
Chief Financial & Business Officer
Ms. Molly Henderson CPA, MBA
Co-Founder
Dr. Aditya Kohli Ph.D.
Chief People Officer
Mr. Paul Cocja
Show More
Chief Development Sciences Officer
Mr. Tom Harris
Chief Medical Officer
Dr. Eckhard Leifke M.D., Ph.D.
Chief Commercial Officer
Mr. Martin J. Gilligan
Show Less

See Also

Discover More
What is the Intrinsic Value of one PHAT stock?

The intrinsic value of one PHAT stock under the Base Case scenario is 12.09 USD.

Is PHAT stock undervalued or overvalued?

Compared to the current market price of 9.28 USD, Phathom Pharmaceuticals Inc is Undervalued by 23%.

Back to Top